Cancer is defined as abnormal cell growth that grows without control; they differ from normal cell in terms of growth. They continue to grow and do no die like the normal cells. Globally, cancer is one of the major causes of death and it accounted for 8.2 million deaths worldwide, in 2012.The increasing prevalence is one of the key factors of the growing oncology biomarkers market.
A biomarker is physical, biological or chemical parameters which are used to indicate a disease condition.
Oncology biomarkers are used in the early detection and screening of cancer, it is a non-invasive, high-speed diagnosis method. There is a growing demand in the oncology biomarker market due to its ability to target molecular structure which is patient-specific and also it accurately traces the cancer type.
On the basis of discovery type the oncology biomarker market is segmented into: metabolomics, genetic methods, protein methods and Imaging. The genetic methods, protein methods are gaining a foot hold in the market due to its growing worldwide adoption.
The major limitation of this market is low benefit-cost ratio of biomarkers and high investment. Sample and storage and validation procedure of the biomarker are the various other limitations of this market.
The market has various opportunities due to the various treatment initiatives taken which is biomarker-based.
Government based agencies such as FDA and NCI have taken initiatives to promote biomarker-based treatment due to the failure rate of drugs used in oncology treatment.
Based on geography the market is segmented into North America, Europe, Asia and RoW. North America leads the oncology biomarker market due to increasing survival rates, streamlined process of drug delivery, increasing private and government funding are few of the factors boosting the growth of the North American region. The North American region is followed by the Europe region as the second highest market.
The major players in this market are Abbott Laboratories, Biocurex Inc., Correlogic Systems, Inc., Agendia Bv, Astellas Pharma US Inc., Biomerieux S.A., Dickinson And Company, Becton, Aureon Laboratories, Inc., Diadexus, Inc., Ambrilia Biopharma, Affymetrix, Inc., Clarient, Inc, Beckman Coulter, Inc., and Biomoda, Inc.
The major developments upon which the key players are focusing is profiled in detail in the report. The report also gives comprehensive and detailed insights about the segments in particular countries in the geographic analysis. It presents in-depth competitive landscape covering major developments in the region for last four years (2012 to 2015), and also the region specific company share analysis for the year 2014.
